Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059338 | 0.89 | GAA (0.49) | MEN1KMT2AMAOADHCR7ACHE | |
| SCHEMBL3052820 | 0.89 | ROCK2 (0.55) | MEN1KMT2ADHCR7PTGER4PTGER2 | |
| SCHEMBL3052615 | 0.88 | CA9 (0.59) | MEN1KMT2ACA2CA9MAOA | |
| SCHEMBL3171188 | 0.86 | GRM5 (0.56) | MEN1KMT2AMAOAACHE | |
| SCHEMBL3055755 | 0.84 | P2RX3 (0.47) | WDR5MEN1KMT2ACA2CA9 | |
| SCHEMBL3054937 | 0.81 | CA9 (0.54) | MEN1KMT2ACA2CA9MAOA | |
| SCHEMBL3058938 | 0.80 | HDAC3 (0.47) | MEN1KMT2AMAOA | |
| SCHEMBL3051832 | 0.79 | CHRNA7 (0.53) | MEN1KMT2ATNIK | |
| SCHEMBL3061473 | 0.79 | ACHE (0.50) | MEN1KMT2AMAOATNIKROCK2 | |
| SCHEMBL24886247 | 0.78 | WDR5 (0.46) | WDR5KMT2APTGER4PTGER2TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | claimed |
| US-8394825-B2 | Compound | STERIX LIMITED (GB) | 2013-03-12 | — | — | US | disclosed |
| US-20100222299-A1 | COMPOUND | STERIX LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222299-A1 | COMPOUND | MKI67, VHL, MYC | WDR5 1862/4885MEN1 305/4885KMT2A 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.